# Does the mAxialtrode Solve the Single-Point Limitation of Conventional Brain Probes?

A single flexible fiber less than half a millimeter in diameter can now simultaneously record electrical activity, deliver drugs to discrete depths, and apply optical stimulation across multiple brain regions — at least in mice. Researchers from DTU, the University of Copenhagen, and University College London published the device, called the microfluidic Axialtrode (mAxialtrode), in *Advanced Science* on September 21, 2026. The implant's key structural feature is eight microscopic channels running alongside a light-conducting core, with drug-delivery points spaced almost three millimeters apart along the fiber's length. In vivo mouse experiments demonstrated simultaneous recording from both cortex and hippocampus, blue and red light stimulation of neurons, and injection of distinct substances at separate depths — all through one implant. The lead developers, Postdoc Kunyang Sui and Associate Professor Christos Markos of DTU, are now pursuing patent protection and evaluating the requirements for first-in-human testing. Clinical use remains distant: the team explicitly states that extensive additional development and regulatory approval are required before patient use.

---

## What the mAxialtrode Actually Is

The device starts as a polymer rod that is heated and drawn — a process analogous to fiber-optic manufacturing — into an extremely thin strand. The finished fiber measures **less than half a millimeter** in diameter.

Internally, the architecture is:
- A **light-conducting core** capable of carrying both blue and red wavelengths for [optogenetics](https://bciintel.com/glossary/brain-computer-interface)-style stimulation
- **Eight microscopic channels** that can carry fluids for localized drug delivery or hold thin metal wires for electrical recording
- A **specially angled tip** designed to reduce insertion trauma compared to flat-ended conventional fibers

The critical engineering advance is axial multimodality: conventional optical fibers interact with tissue only at the distal tip, restricting researchers to one depth at a time. The mAxialtrode's channels and recording sites are distributed along the fiber's length, enabling simultaneous access to multiple anatomical layers without inserting separate devices for each target.

---

## What the Mouse Experiments Showed

The in vivo validation — conducted in collaboration with Associate Professor Rune W. Berg (University of Copenhagen) and Associate Professor Rob C. Wykes (University College London) — demonstrated three concurrent capabilities in living animals:

1. **Optical stimulation** using both blue and red light to activate distinct neural populations
2. **Electrophysiological recording** from the cerebral cortex and hippocampus simultaneously
3. **Localized drug delivery** at injection points separated by approximately **three millimeters** along the implant's length

The mice carried the lightweight fiber without observable signs of discomfort during experiments, which is a meaningful behavioral metric at this early stage, though not a formal biocompatibility endpoint.

The choice of hippocampus and cortex as simultaneous recording targets is scientifically deliberate: epileptic seizures, memory consolidation, and decision-making circuits all depend on cortico-hippocampal communication across those layers. Being able to record and perturb both regions with a single, minimally disruptive implant is the specific gap this device is designed to fill.

---

## The Biocompatibility Argument — and Its Limits

Most clinically deployed intracortical arrays — Utah arrays, tungsten microwires, silicon shanks — are fabricated from rigid materials that generate a mechanical mismatch with soft brain tissue. This mismatch drives the foreign-body response: astrocytic encapsulation, microglial activation, and progressive signal degradation over months to years. [Device longevity](https://bciintel.com/glossary/device-longevity) is among the most consequential unsolved problems in the field.

The mAxialtrode's polymer construction and sub-millimeter diameter are intended to reduce this mismatch. The team specifically highlights the fiber's flexibility as a feature that allows it to move with brain tissue rather than exerting chronic shear stress. This is a well-established hypothesis in the neural probe literature, and the mouse data is consistent with it — but mouse experiments, by definition, cannot tell us how the device performs over the multi-year implant lifetimes that clinical applications require. Chronic biocompatibility in non-human primates, let alone humans, remains uncharacterized.

---

## Clinical Translation: A Realistic Timeline

Sui is direct in tempering expectations: the mAxialtrode is currently a **research tool**, not a therapeutic device. The path to clinical use requires:

- Chronic implant stability data beyond the acute mouse experiments
- Non-human primate studies demonstrating safety and efficacy at relevant anatomical scale
- Manufacturing scale-up and sterilization validation
- An IDE (Investigational Device Exemption) filing with the FDA before any first-in-human use in the U.S.
- Equivalent regulatory pathways in EU (MDR) and other jurisdictions

The team is pursuing patent protection and "exploring what would be required" for clinical testing — language that suggests early-stage conversations rather than an imminent IND or IDE submission. Realistically, first-in-human feasibility studies for a device at this maturity level are likely five to ten years away under an optimistic regulatory trajectory, contingent on sustained funding and a defined clinical indication.

Epilepsy is the most tractable near-term indication. [NeuroPace](https://bciintel.com/companies/neuropace)'s RNS System has already demonstrated the commercial and clinical viability of [closed-loop](https://bciintel.com/glossary/closed-loop) neural stimulation for drug-resistant focal epilepsy. A device that can simultaneously map seizure onset zones with electrophysiology, modulate activity with optogenetics, and deliver anti-epileptic agents locally — without the multi-device surgical burden — would be a substantively differentiated product if it clears the biocompatibility and chronic stability hurdles.

---

## Industry Implications

The mAxialtrode represents a convergence of three technology streams that the BCI industry has largely pursued in parallel: **high-density electrophysiology** (the domain of Utah arrays and Neuropixels probes), **optogenetics delivery** (optical fiber implants), and **intracranial drug delivery** (convection-enhanced delivery catheters). Combining them in a single sub-0.5mm fiber is architecturally novel.

For the research tool market, the device could shorten experiment timelines significantly — eliminating the need to coordinate multiple implanted devices and their associated signal crosstalk and surgical footprint. That has immediate commercial relevance for academic and pharmaceutical neuroscience applications even before clinical translation.

For clinical BCI developers, the more important signal is the manufacturing method. The thermal drawing process that produces the mAxialtrode is scalable and relatively low-cost compared to photolithographic silicon probe fabrication. If the [biocompatibility](https://bciintel.com/glossary/biocompatibility) data holds up at longer time scales, this fabrication approach could pressure existing silicon-based probe manufacturers on both cost and tissue response.

*Note: All results described above are from acute preclinical mouse experiments published in a single study. No human data exists. This is not medical advice. Clinical claims from this research require independent replication and regulatory review before translation to patients.*

---

## Key Takeaways

- The **mAxialtrode** is a polymer optical fiber under **0.5mm** in diameter integrating electrophysiology, optogenetics, and microfluidic drug delivery in one implant
- Eight internal microchannels enable drug or fluid delivery at points spaced **~3mm apart** along the fiber's length
- In vivo mouse experiments confirmed simultaneous cortical and hippocampal recording, dual-wavelength optical stimulation, and depth-resolved drug injection
- The fiber's soft polymer construction is designed to reduce the mechanical mismatch that drives chronic inflammatory responses in rigid silicon implants
- Developers at DTU, University of Copenhagen, and UCL are pursuing patent protection; clinical use requires extensive additional development and regulatory approval
- Epilepsy is the most tractable near-term clinical indication, but first-in-human studies are realistically years away
- The thermal drawing fabrication method is inherently scalable and could influence cost structures in the neural probe market

---

## Frequently Asked Questions

**What is the mAxialtrode and how does it work?**
The mAxialtrode (microfluidic Axialtrode) is a flexible, needle-thin brain implant less than 0.5mm in diameter. It consists of a light-conducting core surrounded by eight microscopic channels that can carry fluids for drug delivery or hold metal wires for electrical recording. Unlike conventional optical fibers that only interact with brain tissue at their tip, the mAxialtrode has functional points distributed along its length, enabling simultaneous recording, stimulation, and drug delivery at multiple brain depths.

**Has the mAxialtrode been tested in humans?**
No. All published results are from acute preclinical experiments in mice, conducted by teams at DTU, the University of Copenhagen, and University College London. The developers state explicitly that extensive additional testing and regulatory approval are required before the device could be used in patients.

**How is this different from existing neural probes like Utah arrays or Neuropixels?**
Existing silicon-based probes excel at high-channel-count electrophysiology but are mechanically rigid and do not natively integrate drug delivery or optical stimulation. Conventional optical fibers used in optogenetics experiments interact only at the distal tip. The mAxialtrode combines all three modalities in a single soft-polymer fiber, potentially reducing the surgical footprint and the chronic inflammatory response associated with rigid implants.

**What neurological conditions could the mAxialtrode eventually treat?**
The researchers specifically cite epilepsy as a target application, given the device's ability to map and modulate activity across multiple brain layers simultaneously. Memory disorders and other conditions involving multi-region circuit dysfunction are mentioned as longer-term research targets. No therapeutic claims are supported by current data.

**What regulatory steps are needed before clinical use?**
In the United States, the device would require an Investigational Device Exemption (IDE) from the FDA before first-in-human studies, preceded by chronic animal safety studies and manufacturing validation. The equivalent pathway in Europe falls under the Medical Device Regulation (MDR). The team has not announced an IDE filing or a specific clinical trial timeline.